PepDiana
Back to Evidence
Primary experimental recordNegative / threshold

PMC12972984::ACT039557

MAVP

Evidence text

Paper-level observation

both GelMA MPs and GelMAMAVP MPs constructs maintained cell viability exceeding 95%, confirming that neither the carrier system nor the anti-VEGFR2 peptide components exhibited significant cytotoxicity (Fig. 1D).
textConfidence: medium

Assay observation

Activity
Toxicity
Subtype
Cytotoxic
Measure
cell_viability
Comparator
>
Raw observation
>95%
Normalized measurement
>95%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
HUVEC; RSC
Assay method
Not reported by source
Sequence
MAGGGATWLPPR
Standardization
ready simple

Source publication

Targeting VEGFR2 inhibition within a spatially-confined conduit promotes nerve self-resolution and alleviates mechanical allodynia

Bioactive Materials · 2026

DOI 10.1016/j.bioactmat.2026.03.009 PMC12972984
Parent mention

Related peptide identities

PEPDIA-PLP-001965

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.